| P50 | author | Teng-Yu Lee | Q47132560 |
| P2093 | author name string | Hong-Zen Yeh | |
| | Shou-Wu Lee | |
| | Yao-Kuang Huang | |
| | Sz-Iuan Shiu | |
| | Chieh-Ling Yen | |
| | Pi-Yi Chang | |
| P2860 | cites work | Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. | Q50323331 |
| | Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. | Q53558959 |
| | Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification | Q83141279 |
| | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84424049 |
| | Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study | Q85026135 |
| | Global cancer statistics, 2012 | Q27860501 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 |
| | Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 |
| | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma | Q33412612 |
| | Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma | Q33787615 |
| | Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases | Q34575821 |
| | Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis | Q34659148 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review | Q35207736 |
| | Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice | Q36009272 |
| | Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease | Q36357360 |
| | The secret of immortal time bias in epidemiologic studies. | Q37102912 |
| | Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. | Q38109951 |
| | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 |
| | Prognosis of untreated hepatocellular carcinoma. | Q39126855 |
| | Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. | Q39334991 |
| | Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? | Q39802942 |
| | Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation | Q41277166 |
| | Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design | Q43950860 |
| | Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis | Q44347050 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma | Q46135283 |
| | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Q50091613 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0188999 | |
| P577 | publication date | 2017-11-30 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma | |
| P478 | volume | 12 | |